Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice

Journal of Nuclear Medicine

Volumn 43, Issue 11, 2002, Pages 1507-1529

  Juweid, Malik E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

B cell non Hodgkin's lymphoma; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ARSENIC; BISMUTH 213; CHLORAMBUCIL; COPPER 67; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; ERYTHROPOIETIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD22; MONOCLONAL ANTIBODY CD37; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RHENIUM 186; RHENIUM 188; RITUXIMAB; STREPTAVIDIN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90;

ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MYELODYSPLASIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; YTTRIUM RADIOISOTOPES;

EID: 0036840133     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
2. Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
3. Witzig T, White C, Wiseman G, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
4. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res. 1999;5(10 suppl):3281s-3286s.
5. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B-cell lymphoma by I-131 Lym-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49-53.
6. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B-cell lymphoma and leukemia using 1-131 Lym-1 monoclonal antibody. Antibody Immunoconjug Radiopharm. 1988;1:17-33.
7. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of B-cell malignancies with I-131 Lym-1 monoclonal antibodies. Int J Cancer. 1988;3(suppl):96-101.
8. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with 1-131 Lym-1. Cancer Res. 1990;50(suppl):1014-1016.
9. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effects of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer. 1994;73:1420-1432.
10. DeNardo GL, DeNardo GL, Goldstein DS, et al. Maximum tolerated dose, toxicity, and efficacy of 1-131 Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
11. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-I (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038.
12. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol. 1992;10:1696-1711.
13. 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res. 1990;50(3 suppl):1022s-1028s.
14. Scheinberg DA, Straus DJ, Yeh SD, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression. J Clin Oncol. 1990;8:792-803.
15. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
16. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
17. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
18. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
19. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, and anti-CD22 monoclonal antibody. Cancer Res. 1995;55(23 suppl):5899s-5907s.
20. 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;38:91-101.
21. DeNardo GL. The next generation of imaging and therapeutic agents for lymphoma and chronic lymphocytic leukemia. New Perspect Cancer Diagn Manage. 1995;3:76-83.
22. O'Donnell RT, Shen S, DeNardo SJ, et al. A phase 1 study of Y-90-21T-BAD-Lym1 in patients with non-Hodgkin's lymphoma. Anticancer Res. 2000;20:3647-3655.
23. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
24. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5(10 suppl):3292s-3303s.
25. 186Re-labeled humanized monoclonal antibody LL2 in patients with non-Hodgkin's lymphoma [abstract]. J Nucl Med. 2000;41(suppl):269P.
26. Wiseman G, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood. 2002;99:4336-4342.
27. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:2453-2463.
28. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
29. Witzig TE, White C, Gordon L, et al. Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 2001;98:606a.
30. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000;18:1316-1323.
31. Gregory SA, Leonard J, Coleman M. et al. Bexxar™ (tositumomab, iodine 131 tositumomab) can be safely administered in relapsed low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) patients after prior treatment with rituximab: Initial experience from the expanded access study [abstract]. Blood. 1999;94(10 suppl 1):91a.
32. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine 1-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3908-3911.
33. Schenkein DP, Leonard J, Harwood S, et al. Interim safety results of Bexxaf™ in a large multicenter expanded access study [abstract]. Proc Am Soc Clin Oncol. 2001;20:285a.
34. Gockerman J, Gregory S, Harwood S. Interim efficacy results of Bexxar™ in a large multicenter expanded access study [abstract]. Proc Am Soc Clin Oncol. 2001;20:285a.
35. 131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL) [abstract]. J Nucl Med. 2000;41(suppl):79P.
36. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336-340.
37. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
38. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 1-131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphomas: Updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
39. 90Y-hLL2) anti-CD22 monoclonal antibody (MAb) [abstract]. J Nucl Med. 2000;41(suppl):31P.
40. Weiden PL, Bretiz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15-29.
41. 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL) [abstract]. Blood. 1999;94(suppl 1):90a.
42. Press O, Eary J, Liu S, et al. A phase I/II trial of high dose iodine-131-anti-B1 (anti-CD20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B cell lymphoma [abstract]. Proc Am Soc Clin Oncol. 1998;17:3a.
43. 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL [abstract]. Blood. 2001;98:677a-678a.
44. Armitage JO, Mauch PM, Harris NL, Bierman P. Non-Hodgkin's lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:2256-2316.
45. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res. 1989;49:4906-4912.
46. Macklis RM, Beresford BA, Humm JL. Radiobiologic studies of low-dose rate Y-90-lymphoma therapy. Cancer. 1994;73:966-973.
47. O'Donoghue JA. The impact of tumor cell proliferation in radioimmunotherapy. Cancer. 1994;73:974-980.
48. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12(suppl 2):S1-S4.
49. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992;52:6476-6481.
50. Ottonello L, Morone P, Dapino P, Dallegri F. Monoclonal lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood. 1996;87:5171-5178.
51. Yorke ED, Beaumier PL, Wessels BW, Fritzberg AR, Morgan AC Jr. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics. Nucl Med Biol. 1991;18:827-835.
52. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med. 1991;32:174-185.
53. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody Immunoconj Radiopharm. 1991;4:85-97.
54. Harris N, Jaffe E, Stein H, et al. Lymphoma classification proposal: Clarification. Blood. 1995;85:857-860.
55. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
56. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
57. Fisher RI. Treatment of aggressive non-Hodgkin's lymphomas: Lessons from the past 10 years. Cancer. 1994;74:2657-2661.
58. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring more aggressive therapy. J Clin Oncol. 1991;9:211-219.
59. Coiffier B, Haion C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood. 1998;92:1927-1932.
60. Weiner LM, Adams GP, Von Mehren M. Therapeutic monoclonal antibodies: General principles. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:495-508.
61. Nabi H. Antibody tumor imaging. In: Nuclear Medicine Self-Study Program IV: Nuclear Medicine Ontology, Unit 3. Reston, VA: The Society of Nuclear Medicine; 1998:1-37.
62. DeNardo S, DeNardo GL. Radioimmunotherapy. In: Nuclear Medicine Self-Study Program IV: Nuclear Medicine Oncology. Unit 6. Reston, VA: The Society of Nuclear Medicine; 1998:39-74.
63. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
64. Hoffman T, Kenimer J, Stein KE. Regulatory issues surrounding therapeutic use of monoclonal antibodies: Points to consider in the manufacture of injectable products intended for human use. In: Reisfeld RA, Sell S. eds. Monoclonal Antibodies and Cancer Therapy: UCLA Symposia on Molecular and Cellular Biology. New Series. Indianapolis, IN: Wiley: 1985;27:431-440.
65. Juweid M, Swayne LC, Sharkey RM, et al. Prospects of radioimmunotherapy in epithelial ovarian cancer: Results with 1-131-labeled murine and humanized anti-CEA monoclonal antibodies. Gynecol Oncol. 1997;67:259-271.
66. Behr T, Juweid M, Sharkey RM, Swayne LC, Dunn R, Goldenberg DM. Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumors with 1-131-labeled monoclonal antibodies. Nucl Med Commun. 1996;17:767-780.
67. Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol. 1998;81:105-119.
68. Shah SA, Halloran PM, Ferris CA, et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 1993;53:1360-1367.
69. Ghetie M-A, May RD, Till M, et al. Evaluation of ricine A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. J Cancer Res. 1998;48:2610-2617.
70. Behr TM, Wormann B, Gramatzki M, et al. Low-versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res. 1999;5(suppl):3304s-3314s.
71. Hale G, Dyer MI, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-IH. Lancet. 1988;2:1394-1399.
72. Gingrich RD, Dahle CE, Hoskins MF, Senneff MJ. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood. 1990;75:2375-2387.
73. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res. 1988;48:2641-2658.
74. Juweid M, Neumann R, Paik C, et al. The micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence of a binding site barrier. Cancer Res. 1992;52:5144-5153.
75. 2 with the alpha-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149-7153.
76. Jurcic JG, McDevitt MR, Sgouros G, et al. Phase I trial of targeted alpha-particle therapy for myeloid leukemias bismuth-213-HuM195 (anti-CD33) [abstract]. Proc Am Soc Clin Oncol. 1999;18:7a.
77. Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962;194:495-496.
78. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1,3,4,6-tetrachloro-3α,6α-diphenylglycouril. Biochem Biophys Res Commun. 1978;80:849-857.
79. Kozak RW, Raubitschek A, Mirzadeh S, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity. Cancer Res. 1989;49:2639-2644.
80. 90Y-labeled monoclonal antibody COI7-1A. Nucl Med Biol. 1991;18:313-321.
81. Rowlinson G, Snook D, Stewart S, Epenetos AA. Intravenous EDTA to reduce bone uptake of Y-90 following Y-90 labeled antibody administration [abstract]. Br J Cancer. 1989;59:322.
82. 90Y labeled monoclonal antibodies for ovarian cancer: Pharmacokinetics and normal tissue dosimetry. Int J Cancer. 1988;3(suppl):71-76.
83. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugate; after binding to the surface of tumor cells. Cancer, 1994;73:787-793.
84. Duncan JR, Welch MJ. Intracellular metabolism of indium-III-DTPA-labeled receptor targeted proteins. J Nucl Med. 1993;34:1728-1738.
85. 131I with "non-internalizing" monoclonal antibodies (MAbs) [abstract]. Eur J Nucl Med. 1999;26:1190.
86. 90Y-labeled MAbs. Cancer Biother Radiopharm. 1999;14:37-47.
87. DeNardo GL, DeNardo SJ, O'Donnell RT. Are radiometal-labeled antibodies better than 1-131 labeled antibodies: Comparative pharmacokinetics and dosimetry of copper-67, iodine-131- and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2000;1:118-126.
88. Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med. 1994;35:1381-1389.
89. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
90. Juweid M, Sharkey RM, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma with non-myeloablative doses of radiolabeled monoclonal antibodies. In: Riva P, ed. Therapy of Malignancies with Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives. Philadelphia, PA: Harwood Academic Publisher; 1999:245-262.
91. DeNardo GL, Juweid ME, White CA, Wiseman GA, DeNardo SJ. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001;39:203-218
92. 2 anti-CEA monoclonal antibody and autologous hematopoietic stem cell rescue (AHSCR). J Nucl Med. 2000;41:93-103.
93. Zanzonico PB. Internal radionuclide radiation dosimetry: A review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308.
94. Stabin MG. Internal dosimetry in the use of radiopharmaceuticals in therapy: Science at a crossroads? Cancer Biother Radiopharm, 1999;14:81-89.
95. Siegel JA, Wu RK. The elusive buildup factor [abstract]. Med Phys. 1982;6:614.
96. van Rensburg AJ, Latter MG, Heyns AP, Minnear PC. An evaluation of four methods of In-111 planar image quantification. Med Phys. 1988;15:853-861.
97. Sgouros G, Chiu S, Pentlow K, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med. 1993;34:1595-1601.
98. Liu A, Williams LE, Lopatin G, Yamauchi DM, Wong JYC, Raubitschek AA. A radionuclide therapy treatment planning and dose estimation system. J Nucl Med. 1999;40:1151-1153.
99. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990;3:213-233.
100. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med. 1993;34:689-694.
101. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80(suppl):2558-2566.
102. Juweid M, Sharkey RM, Siegel JA, Behr TM, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res. 1995;55(suppl):5827s-5831s.
103. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(suppl):14S-20S.
104. Loevinger R, Berman M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides: MIRD Pamphlet No. 1. New York, NY: Society of Nuclear Medicine; 1976:1-10.
105. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
106. Siegel JA, Thomas SR, Stubbs JB, et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates: MIRD Pamphlet No. 16. J Nucl Med. 1999;40(suppl):37S-61S.
107. 131I-labeled anti-carcinoembryonic antigen monoclonal antibodies [abstract]. Cancer Biother Radiopharm. 1998;13:319.
108. Wiseman G, White CA, Sparks RB, et al. Biodistribution and dosimetry results from the phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell NHL. Crit Rev Oncol Hentatol. 2001;39:181-194.
109. Zevalin [Package Insert]. San Diego, CA: IDEC Pharmaceuticals Corp.; 2002.
110. Erwin WD, Groch MW. Quantitative radioimmunoimaging for radioimmunotherapy treatment planning: Effect of reduction in data sampling on dosimetric estimates. Cancer Biother Radiopharm. 2002;17:in press.
111. 2. J Nucl Med. 1996;37:1504-1510.
112. 2 anti-CEA monoclonal antibody in patients with metastatic medullary thyroid cancer. Cancer. 1999;85:1828-1842.
113. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously-untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biother Radiopharm. 2000;15:347-355.